PT2162462T - Um polipéptido antagonista do recetor 4 de quimiocina cxc (cxcr4) - Google Patents

Um polipéptido antagonista do recetor 4 de quimiocina cxc (cxcr4)

Info

Publication number
PT2162462T
PT2162462T PT87746913T PT08774691T PT2162462T PT 2162462 T PT2162462 T PT 2162462T PT 87746913 T PT87746913 T PT 87746913T PT 08774691 T PT08774691 T PT 08774691T PT 2162462 T PT2162462 T PT 2162462T
Authority
PT
Portugal
Prior art keywords
cxcr4
chemokine receptor
cxc chemokine
antagonistic polypeptide
antagonistic
Prior art date
Application number
PT87746913T
Other languages
English (en)
Inventor
Georg Forssmann Wolf
Kirchhoff Frank
Münch Jan
Staendker Ludger
Original Assignee
Pharis Biotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharis Biotec Gmbh filed Critical Pharis Biotec Gmbh
Publication of PT2162462T publication Critical patent/PT2162462T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
PT87746913T 2007-07-03 2008-07-03 Um polipéptido antagonista do recetor 4 de quimiocina cxc (cxcr4) PT2162462T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007030904A DE102007030904A1 (de) 2007-07-03 2007-07-03 Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung

Publications (1)

Publication Number Publication Date
PT2162462T true PT2162462T (pt) 2018-01-31

Family

ID=39760841

Family Applications (2)

Application Number Title Priority Date Filing Date
PT171921778T PT3275894T (pt) 2007-07-03 2008-07-03 Um polipéptido antagonístico do recetor 4 de quimiocina cxc (cxcr4)
PT87746913T PT2162462T (pt) 2007-07-03 2008-07-03 Um polipéptido antagonista do recetor 4 de quimiocina cxc (cxcr4)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT171921778T PT3275894T (pt) 2007-07-03 2008-07-03 Um polipéptido antagonístico do recetor 4 de quimiocina cxc (cxcr4)

Country Status (12)

Country Link
US (1) US9045563B2 (pt)
EP (2) EP2162462B1 (pt)
JP (2) JP2010531655A (pt)
CN (1) CN101730709B (pt)
CA (2) CA2691061C (pt)
DE (1) DE102007030904A1 (pt)
DK (2) DK2162462T3 (pt)
ES (2) ES2655289T3 (pt)
HU (2) HUE047454T2 (pt)
PL (2) PL3275894T3 (pt)
PT (2) PT3275894T (pt)
WO (1) WO2009004054A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
EP2799877A1 (en) * 2013-05-03 2014-11-05 Universität Ulm Process for diagnosing a human subject with diseases affecting the kidneys, or at risk of acquiring diseases affecting the kidneys
LT3007717T (lt) * 2013-06-12 2018-11-26 Pharis Biotec Gmbh Peptidai su antagonistiniu veikimu prieš gamtinį cxcr4
CN104292302B (zh) * 2013-07-16 2018-05-04 国家纳米科学中心 一种增强肿瘤细胞对抗肿瘤药物敏感性的多肽及其应用
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
WO2016013828A1 (ko) 2014-07-21 2016-01-28 연세대학교 산학협력단 황산화된 더피 케모카인 수용체의 세포 외 도메인 1 변이체 및 이의 용도
WO2016079143A1 (de) 2014-11-17 2016-05-26 Pharis Biotec Gmbh Inhibitor der viralen hepatitis c infektion
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
JP7274228B2 (ja) * 2017-09-08 2023-05-16 ネオペプ ファーマ ゲーエムベーハー ウント コンパニー カーゲー 病気の治療のためのポリペプチド
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
EP3877396A1 (en) * 2018-11-09 2021-09-15 Neopep Pharma GmbH & Co. KG Polypeptides for the treatment of stress, immunoreaction and stroke syndromes
EP3872084A1 (en) * 2020-02-27 2021-09-01 Universität Ulm Epi-x4 based peptides and derivatives thereof
WO2023099725A1 (de) * 2021-12-02 2023-06-08 Pharis Biotec Gmbh Pharmazeutische zubereitung enthaltend eine mischung eines natriuretischen peptids (anp) und eines peptidischen hemmstoffs des cxcr4-rezeptors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255130T1 (de) * 1997-09-16 2003-12-15 Wolf-Georg Forssmann Bifidogene peptide und deren verwendung
CN1195779C (zh) * 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
GB0217347D0 (en) * 2002-07-26 2002-09-04 Univ Edinburgh Novel albumins
DK1987178T3 (en) * 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
CN1872879B (zh) * 2006-06-29 2011-09-14 孙晗笑 来源于病毒巨噬细胞炎性蛋白的cxcr4受体拮抗活性多肽及其应用
EP2423222B2 (en) * 2007-01-30 2020-07-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof

Also Published As

Publication number Publication date
WO2009004054A8 (en) 2017-04-06
WO2009004054A3 (en) 2009-02-26
WO2009004054A2 (en) 2009-01-08
PT3275894T (pt) 2020-02-06
JP2010531655A (ja) 2010-09-30
EP3275894B1 (en) 2019-11-13
CA2968054A1 (en) 2009-01-08
CA2968054C (en) 2022-06-14
CN101730709B (zh) 2013-06-12
ES2770361T3 (es) 2020-07-01
HUE047454T2 (hu) 2020-04-28
DK2162462T3 (da) 2018-01-29
PL3275894T3 (pl) 2020-07-13
JP5941497B2 (ja) 2016-06-29
EP3275894A1 (en) 2018-01-31
CA2691061A1 (en) 2009-01-08
CN101730709A (zh) 2010-06-09
PL2162462T3 (pl) 2018-03-30
ES2655289T3 (es) 2018-02-19
CA2691061C (en) 2017-07-11
JP2014209914A (ja) 2014-11-13
US9045563B2 (en) 2015-06-02
EP2162462B1 (en) 2017-10-25
DE102007030904A1 (de) 2009-02-05
DK3275894T3 (en) 2020-02-03
HUE037931T2 (hu) 2018-09-28
US20130029902A1 (en) 2013-01-31
EP2162462A2 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
PL3275894T3 (pl) Antagonistyczny polipeptyd receptora 4 chemokiny cxc (cxcr4)
TWI346553B (en) Chemokine receptor antagonists
EP2099454A4 (en) AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
EP1871752A4 (en) ANTAGONISTS OF THE AMIDOPROPOXYPHENYLOREXIN RECEPTOR
EP1613613A4 (en) CXCR4-CHEMOKIN RECEPTOR BINDING COMPOUNDS
TWI341198B (en) Hydroisoindoline tachykinin receptor antagonists
IL192426A0 (en) Prokineticin 2 receptor antagonists
HK1141474A1 (en) Cyclic peptide cxcr4 antagonists
IL187424A0 (en) C5a RECEPTOR ANTAGONISTS
EP1924265A4 (en) COMPOUNDS BINDING TO CHEMOKINE RECEPTORS
IL190686A0 (en) Il-21 receptor antagonists
IL192424A0 (en) Prokineticin 1 receptor antagonists
HUP0600858A2 (en) Piperizinyilpiperidine derivatives as chemokine receptor antagonists
ZA200705237B (en) C5A receptor antagonists
EP2170064A4 (en) 6,5-pyrrolopiperidine tachykinin receptor antagonists
EP1896023A4 (en) CHEMOKINE RECEPTOR BINDING COMPOUNDS
ZA200609461B (en) High affinity NY-ESO T cell receptor
IL205749A0 (en) Modified il-4 mutein receptor antagonists
EP1942890A4 (en) CHEMOKINE RECEPTOR BINDING COMPOUNDS
EP1898905A4 (en) ANTAGONISTS OF TACHYKININ HYDRO-ISO-INDOLIC RECEPTORS
AP2008004537A0 (en) Muscarinic receptor antagonists
ZA200605574B (en) Hydroisoindoline tachykinin receptor antagonists
GB0525029D0 (en) Receptor Antagonist
ZA200806223B (en) Muscarinic receptor antagonists
GB0405642D0 (en) Cytokine receptor